Developer docs
API playgroundTry for free, no card

Search company profiles

BVF Partners

Full company profile

uuid02l8dp6

Namestring
BVF Partners
Legal namestring
BVF Partners L.P.
Websiteurl
bvfpartners.com
Company typeenum
Private
Founded yearint
1993
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biotech investment management, life sciences hedge fund, healthcare equity financing, clinical-stage biotech funding, private placement investing
Industry1 code
1Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryYes
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Biotech Hedge Fund Management
No data
Cost components4 values
Personnel, Operations, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BVF Partners is a San Francisco-based investment firm, operating as BVF Partners L.P., that manages hedge funds focused exclusively on biotechnology and life sciences companies. The firm deploys capital into clinical-stage biotech companies via private placements, post-IPO equity offerings, and Series B financings, both as lead investor and as a participating institutional investor.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

BVF Partners L.P. is a healthcare-focused investment firm specializing in biotech investments. The company does not offer technology products or services but rather provides investment capital to biotechnology companies through private placements, equity financings, and other investment mechanisms. As an investment fund, BVF Partners participates in funding rounds for companies including Absci Corporation, Entera Bio, Immunic, Ambrosia Biosciences, MoonLake Immunotherapeutics, and others developing pharmaceutical and biotechnology therapies.

Product and service1 record
1BVF Partners L.P. Biotech Hedge Fund
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Baker Bros. Advisors
TypeDirect peer
Description

Long-standing biotech-specialist investment advisor with a virtually identical mandate to BVF — public and private equity investments in clinical-stage life sciences companies.

TypeBroad incumbent
Description

Large diversified asset manager participating in biotech financings (e.g., Diagonal Therapeutics) as one of many verticals; less specialized than BVF but a co-investor in the same deals.

TypeDirect peer
Description

Biotech-specialist investment firm with comparable clinical-stage focus and active role in private placements and PIPEs across the same universe of issuers.

TypeDirect peer
Description

Biotech-specialist hedge fund that co-invests with BVF in private placements and PIPE financings, sharing a comparable biotech-only mandate.

TypeDirect peer
Description

Healthcare-focused investment manager with a similar biotech equity mandate, frequently participating alongside BVF in mid-cap clinical-stage financings.

TypeDirect peer
Description

Healthcare-focused crossover fund frequently co-investing alongside BVF in biotech PIPE and private placements; near-perfect mandate overlap on clinical-stage therapeutics.

TypeDirect peer
Description

Healthcare-dedicated investment firm across private equity, venture, and public equity — directly comparable to BVF's biotech focus and similar financing role in deals such as Immunic.

TypeDirect peer
Description

Healthcare-focused investment firm co-leading deals alongside BVF (e.g., Ambrosia Biosciences Series B) with overlapping biotech-only investment universe.

TypeDirect peer
Description

Healthcare investment manager combining public equities and venture/private capital; co-investor with BVF in financings such as Foghorn Therapeutics.

TypeDirect peer
Description

Biotech-focused fund co-investing with BVF in Immunic's placement; near-identical clinical-stage biotech mandate.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BVF Partners

Biotech Hedge Fund Managementbvfpartners.com

BVF Partners firmographics

Firmographics
Name
BVF Partners
Legal name
BVF Partners L.P.
Website
https://bvfpartners.com
Company type
Private
Founded year
1993
Operating status
Operating
Ownership category
akta.pro rank

BVF Partners industry classification

Industry
Product category
Biotech Hedge Fund Management
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro primary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

  • Biotech investment management
  • Life sciences hedge fund
  • Healthcare equity financing
  • Clinical-stage biotech funding
  • Private placement investing

Where BVF Partners is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

BVF Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Others

BVF Partners product offering

Product offering

Core offering

BVF Partners is a San Francisco-based investment firm, operating as BVF Partners L.P., that manages hedge funds focused exclusively on biotechnology and life sciences companies. The firm deploys capital into clinical-stage biotech companies via private placements, post-IPO equity offerings, and Series B financings, both as lead investor and as a participating institutional investor.

Product overview

BVF Partners L.P. is a healthcare-focused investment firm specializing in biotech investments. The company does not offer technology products or services but rather provides investment capital to biotechnology companies through private placements, equity financings, and other investment mechanisms. As an investment fund, BVF Partners participates in funding rounds for companies including Absci Corporation, Entera Bio, Immunic, Ambrosia Biosciences, MoonLake Immunotherapeutics, and others developing pharmaceutical and biotechnology therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • BVF Partners L.P. Biotech Hedge Fund

Companies that use BVF Partners

Customer profile

Ideal customer profiles2 records

BVF Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BVF Partners partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights3 records

BVF Partners competitors and assessment

Company assessment

Direct peers

  • Baker Bros. Advisors: Long-standing biotech-specialist investment advisor with a virtually identical mandate to BVF — public and private equity investments in clinical-stage life sciences companies.
  • Perceptive Advisors: Biotech-specialist investment firm with comparable clinical-stage focus and active role in private placements and PIPEs across the same universe of issuers.
  • EcoR1 Capital: Biotech-specialist hedge fund that co-invests with BVF in private placements and PIPE financings, sharing a comparable biotech-only mandate.
  • Cormorant Asset Management: Healthcare-focused investment manager with a similar biotech equity mandate, frequently participating alongside BVF in mid-cap clinical-stage financings.
  • RA Capital Management: Healthcare-focused crossover fund frequently co-investing alongside BVF in biotech PIPE and private placements; near-perfect mandate overlap on clinical-stage therapeutics.
  • OrbiMed Advisors: Healthcare-dedicated investment firm across private equity, venture, and public equity — directly comparable to BVF's biotech focus and similar financing role in deals such as Immunic.
  • Redmile Group: Healthcare-focused investment firm co-leading deals alongside BVF (e.g., Ambrosia Biosciences Series B) with overlapping biotech-only investment universe.
  • Deerfield Management: Healthcare investment manager combining public equities and venture/private capital; co-investor with BVF in financings such as Foghorn Therapeutics.
  • Avidity Partners: Biotech-focused fund co-investing with BVF in Immunic's placement; near-identical clinical-stage biotech mandate.

Broad incumbents

  • Janus Henderson Investors: Large diversified asset manager participating in biotech financings (e.g., Diagonal Therapeutics) as one of many verticals; less specialized than BVF but a co-investor in the same deals.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

BVF Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BVF Partners leadership team

Management profile

Number of profiles

BVF Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BVF Partners M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BVF Partners

What does BVF Partners do?

BVF Partners is a San Francisco-based investment firm, operating as BVF Partners L.P., that manages hedge funds focused exclusively on biotechnology and life sciences companies. The firm deploys capital into clinical-stage biotech companies via private placements, post-IPO equity offerings, and Series B financings, both as lead investor and as a participating institutional investor.

Is BVF Partners a public or private company?

BVF Partners is a private company. It is classified as unknown and is currently operating.

When was BVF Partners founded?

BVF Partners was founded in 1993.

Where is BVF Partners based?

BVF Partners is headquartered in San Francisco, United States, in the North America region.

Who are BVF Partners's main competitors?

Direct peers on record are Baker Bros. Advisors, Perceptive Advisors, EcoR1 Capital, Cormorant Asset Management, RA Capital Management, OrbiMed Advisors, Redmile Group, Deerfield Management and Avidity Partners. Janus Henderson Investors is listed as a broad incumbent.

Does BVF Partners have an API?

No public API is recorded for BVF Partners.

What industry is BVF Partners in?

BVF Partners's product category is Biotech Hedge Fund Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded WarrantsSagimet Biosciences closed an underwritten offering of 8,750,010 Series A shares at $10 each, with pre-funded warrants as an alternative. Gross proceeds were approximately $115 million, led by Commodore Capital. The company will use net proceeds to fund a Phase 3 trial for denifanstat in acne and other development activities.San Diego Business JournalKura Oncology Carves Out Diabetes Treatment Co.Kura Oncology carved out Caspian Therapeutics to develop its menin inhibitor KO-7246 for diabetes and cardiometabolic diseases. The new company raised $50 million from Eli Lilly and existing investors, with Kura retaining half ownership. Caspian will pursue preclinical studies, an IND application, and clinical trials.pharmaphorumEncoded raises $275m for Dravet therapy and other financingsEncoded Therapeutics raised $275 million to advance its Dravet syndrome gene therapy ETX101 into a pivotal trial, following phase 1/2 POLARIS data showing reduced seizure frequency. The funding will also support manufacturing scale-up and development of a second drug candidate, ETX301, for post-amputation pain.YahooKura Oncology Pivots Diabetes Strategy Into $50 Million SubsidiaryKura Oncology announced a $50 million financing led by BVF Partners to launch Caspian Therapeutics, advancing its menin-inhibition strategy for diabetes. The funds will support development of lead asset KO-7246 and a second candidate, with Kura retaining about half ownership.BenzingaKura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary - Kura Oncology (NASDAQ:KURA)Kura Oncology announced a $50 million financing led by BVF Partners to launch Caspian Therapeutics, advancing its menin-inhibition strategy for diabetes. The funds will support development of lead asset KO-7246 through IND-enabling and initial clinical proof-of-concept. Kura will retain about half ownership and board representation.The Pharma LetterKura launches new company, diabetes focused Caspian TherapeuticsKura Oncology launched Caspian Therapeutics, a separately financed company developing small-molecule menin inhibitors for diabetes and cardiometabolic diseases. The company raised $50 million led by BVF Partners, with Kura retaining about 50% ownership.FierceBiotechKura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapyKura Oncology spun out Caspian Therapeutics with $50M in funding to advance KO-7246, a menin inhibitor for diabetes. The round was led by BVF Partners with Eli Lilly and T1D Fund. Kura will own half and present preclinical data at the EASD meeting in Milan.GlobeNewswireKura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for DiabetesKura Oncology launched Caspian Therapeutics, a separately financed company advancing menin inhibitors for diabetes, with a $50 million financing led by BVF Partners. Preclinical data on KO-7246 showed selective β-cell expansion and improved glycemic control, and the company plans an IND-enabling development and initial clinical proof-of-concept.KuraoncologyKura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for DiabetesKura Oncology launched Caspian Therapeutics, a separately financed company advancing menin inhibitors for diabetes, with a $50 million financing led by BVF Partners. Preclinical data on KO-7246 showed selective β-cell expansion and improved glycemic control, and the company plans to submit an IND for clinical proof of concept.WowtaleGPCR 신약개발 AI 슈퍼루미널, 6천만 달러 시리즈B 유치Superluminal Medicines raised $60 million in a Series B led by BVF Partners, exceeding its target. The Boston biotech uses AI and cryo-EM to target GPCRs, with a pipeline targeting MC4R for rare genetic obesity, aiming for Phase 1 this year. It also partners with Eli Lilly on cardiovascular and metabolic GPCR targets.